『徳島大学 教育・研究者情報データベース (EDB)』---[学外] /
ID: Pass:

登録内容 (EID=342245)

EID=342245EID:342245, Map:0, LastModified:2018年8月27日(月) 20:21:42, Operator:[大家 隆弘], Avail:TRUE, Censor:0, Owner:[久保 宜明], Read:継承, Write:継承, Delete:継承.
種別 (必須): 学術論文 (審査論文) [継承]
言語 (必須): 英語 [継承]
招待 (推奨):
審査 (推奨):
カテゴリ (推奨):
共著種別 (推奨):
学究種別 (推奨):
組織 (推奨):
著者 (必須): 1. (英) Yamasaki K (日) (読)
役割 (任意):
貢献度 (任意):
学籍番号 (推奨):
[継承]
2. (英) Nakagawa H (日) (読)
役割 (任意):
貢献度 (任意):
学籍番号 (推奨):
[継承]
3.久保 宜明 ([徳島大学.大学院医歯薬学研究部.医学域.医科学部門.内科系.皮膚科学])
役割 (任意):
貢献度 (任意):
学籍番号 (推奨):
[継承]
4. (英) Ootaki K (日) (読)
役割 (任意):
貢献度 (任意):
学籍番号 (推奨):
[継承]
題名 (必須): (英) Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study.  (日)    [継承]
副題 (任意):
要約 (任意): (英) A T-helper (Th) cell subset Th17 preferentially produces interleukin (IL)-17 and plays a pivotal role in the pathogenesis of psoriasis. However, the pathological roles of IL-17 cascades in generalized pustular psoriasis (GPP) and psoriatic erythroderma (PsE) have not been well established. To evaluate the efficacy and safety of brodalumab, a human immunoglobulin G2 monoclonal antibody against human IL-17-receptor A (IL-17RA), in Japanese patients with GPP and PsE. This was an open-label, multicentre, long-term phase III study in Japanese patients with rare and severe types of psoriasis. Patients received brodalumab 140 mg at day 1 and weeks 1 and 2, and then every 2 weeks until week 52. The primary endpoint was the Clinical Global Impression of Improvement (CGI). Safety evaluations included treatment-emergent adverse events (AEs) and changes in laboratory parameters. A total of 12 patients with GPP and 18 with PsE were enrolled. Ten patients with GPP and 16 with PsE completed the study. At week 52 (last observation carried forward), CGI remission or improvement was achieved in 11 patients with GPP and 18 with PsE. The most commonly reported AE was nasopharyngitis (33 3%). Five serious AEs occurred during the study. However, none was considered treatment-related. Brodalumab significantly improved the symptoms of patients with GPP and PsE throughout the 52 weeks, and demonstrated favourable safety profiles without any new safety signals. Inhibition of IL-17RA-mediated signalling by brodalumab is expected to be a promising new treatment option for patients with GPP and PsE.  (日)    [継承]
キーワード (推奨): 1. (英) Adult (日) (読) [継承]
2. (英) Antibodies, Monoclonal (日) (読) [継承]
3. (英) Dermatitis, Exfoliative (日) (読) [継承]
4. (英) Dermatologic Agents (日) (読) [継承]
5. (英) Dose-Response Relationship, Drug (日) (読) [継承]
6. (英) Drug Administration Schedule (日) (読) [継承]
7. (英) Female (日) (読) [継承]
8. (英) Humans (日) (読) [継承]
9. (英) Injections, Subcutaneous (日) (読) [継承]
10. (英) Long-Term Care (日) (読) [継承]
11. (英) Male (日) (読) [継承]
12. (英) Middle Aged (日) (読) [継承]
13. (英) Psoriasis (日) (読) [継承]
14. (英) Treatment Outcome (日) (読) [継承]
発行所 (推奨):
誌名 (必須): The British Journal of Dermatology (British Association of Dermatologists)
(pISSN: 0007-0963, eISSN: 1365-2133)

ISSN (任意): 1365-2133
ISSN: 0007-0963 (pISSN: 0007-0963, eISSN: 1365-2133)
Title: The British journal of dermatology
Title(ISO): Br J Dermatol
Supplier: British Association of Dermatologists
Publisher: Blackwell
 (NLM Catalog  (Wiley  (Scopus  (CrossRef (Scopus information is found. [need login])
[継承]
[継承]
(必須): 176 [継承]
(必須): 3 [継承]
(必須): 741 751 [継承]
都市 (任意):
年月日 (必須): 西暦 2017年 3月 初日 (平成 29年 3月 初日) [継承]
URL (任意):
DOI (任意): 10.1111/bjd.14702    (→Scopusで検索) [継承]
PMID (任意): 27106510    (→Scopusで検索) [継承]
NAID (任意):
WOS (任意):
Scopus (任意):
評価値 (任意):
被引用数 (任意):
指導教員 (推奨):
備考 (任意): 1.(英) Article.ELocationID: 10.1111/bjd.14702  (日)    [継承]
2.(英) Article.PublicationTypeList.PublicationType: Clinical Trial, Phase III  (日)    [継承]
3.(英) Article.PublicationTypeList.PublicationType: Journal Article  (日)    [継承]
4.(英) Article.PublicationTypeList.PublicationType: Multicenter Study  (日)    [継承]

標準的な表示

和文冊子 ● K Yamasaki, H Nakagawa, Yoshiaki Kubo and K Ootaki : Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study., The British Journal of Dermatology, Vol.176, No.3, 741-751, 2017.
欧文冊子 ● K Yamasaki, H Nakagawa, Yoshiaki Kubo and K Ootaki : Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study., The British Journal of Dermatology, Vol.176, No.3, 741-751, 2017.

関連情報

Number of session users = 0, LA = 0.86, Max(EID) = 382774, Max(EOID) = 1022371.